Cue Biopharma reports Q3 EPS (7c), consensus (9c)

Reports Q3 revenue $2.15M, consensus $2.29M. “During the third quarter of 2025 and early in the fourth quarter, the Company made tremendous progress from having successfully implemented a plan of optionality and laying the necessary groundwork for future growth,” said Usman Azam, M.D., president and chief executive officer of Cue Biopharma (CUE). “I am deeply proud of the Cue team and believe we are strategically positioned to further advance our differentiating Immuno-STAT platform and lead autoimmune asset, CUE-401, toward the clinic to address a major unmet need in autoimmune disease treatment.”